Month: August 2021

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 SIX LISTING RULES Geneva, 26 August 2021 ENR RUSSIA INVEST SA ANNOUNCES 2021 HALF-YEAR RESULTS For the six months ended 30 June 2021 ENR Russia Invest SA (“ENR”) and its subsidiaries produced a consolidated net profit of CHF 2.94 million (consolidated net loss of CHF 4.58 million for the similar period in 2020) mainly due to higher valuations arising from ruble appreciation against the Swiss Franc. The consolidated equity increased to CHF 41.05 million (CHF 36.76 million at 31 December 2020). In the reporting period ENR sold shares and fixed income instruments for CHF 2.59 million. Proceeds were used for further investments in Kaluga Flower Holding LLC (ruble 90.4 million or CHF 1.08 million) in Russia, to reinvest in equities (CHF 0.67 million) and to increase cash on hand. At the flower growing...

PRESS RELEASE: REGULATED INFORMATION 26 August 2021, 07:00 CEST BIOCARTIS ANNOUNCES 2021 HALF–YEAR RESULTS ON 2 SEPTEMBER 2021 Mechelen, Belgium, 26 August 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that it will report its 2021 half-year results and outlook for the remainder of the year on 2 September 2021 at 07:00 CEST. The Biocartis management team will host a conference call with live webcast presentation on the day of the results announcement, 2 September 2021 at 14:30h CEST / 13:30h BST (UK) / 08:30h EDT (US).The live webcast can be accessed here. If you would like to participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below and confirmation code 4866873. Dial-ins:Belgium,...

— Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 Research & Development:Initiated two global Phase 2 and 3 trials of ensovibep (MP0420), to explore safety and efficacy in ambulatory patients with COVID-19 (EMPATHY) in collaboration with Novartis, and hospitalized patients (ACTIV-3) sponsored by the National Institutes of Health (NIH) Received FDA Fast Track designation for ensovibep for the treatment of COVID-19 in both hospitalized and ambulatory settings Initiated and fully enrolled Phase 2a single arm study of ensovibep in the Netherlands in patients with mildly symptomatic COVID-19, with data expected to be presented in a scientific conference in H2 2021 Reported that in vitro studies...

Highlights in the second quarter:Solid craftsmanship and good biological performance gave strong results in both farming in Fish Farming Central Norway and Northern Norway in the quarter Negative contribution from fixed-price contracts and higher costs relating to the completion and startup of InnovaNor and the expansion at Vikenco weakened results from Sales and Processing Total operational EBIT for the period (including Icelandic Salmon) totalled NOK 661 million or NOK 18.05 per kg. Operational EBIT for Norway alone came to NOK 633 million or NOK 18.44 per kg The upgrade at Vikenco has been completed while InnovaNor is close to completion and is expected to go into operation in the fourth quarter 2021 Good operational performance and increased price achievement improved Icelandic Salmon’s results SalMar maintains its expectations to...

Q2 2021 Key Highlightsrevenues of $103.3 million adjusted EBITDA of $33.7 million net income of $9.6 million free cash flow of $25.4 millionH1 2021 Key Highlightsrevenues of $193.5 million adjusted EBITDA of $54.3 million net income of $11.5 million free cash flow of $40.1 millionRevised FY 2021 Guidanceincreased adjusted EBITDA guidance to $110-120 million tightened maintenance capex guidance to $22-25 million tightened growth capex guidance to $12-15 million increased free cash flow guidance to $55-65 millionRefinancing Highlightsclosed three-year, $205 million secured term loan repaid existing secured term credit facility amended existing secured working capital facility at Conda to increase the commitment amount from $20 million to $40 million and extend term amended existing unsecured and subordinated promissory note...